Avacta Group PLC represents a strong commitment to innovation, excellence, and high-quality solutions in the healthcare sector. By focusing on developing and commercializing novel biotherapeutics and diagnostics, Avacta Group aims to improve patient outcomes and transform the way diseases are diagnosed and treated. Their corporate philosophy is centered around collaboration, strategic partnerships, and delivering value for all stakeholders. Avacta Group PLC constantly strives to stay at the forefront of cutting-edge technologies and leverage their expertise to address significant medical challenges. With a relentless drive for scientific advancements, Avacta Group PLC aims to revolutionize healthcare by providing innovative and effective solutions to improve global health.

Avacta Group PLC is primarily present in the United Kingdom (UK).

Avacta Group PLC, a leading biotechnology company, has achieved several significant milestones. Firstly, they successfully developed a novel Affimer® technology, revolutionizing the field of protein engineering. Avacta also secured multiple key partnerships with industry leaders, such as LG Chem Life Sciences and Tufts University, to accelerate commercialization. Furthermore, the company obtained regulatory approval for their rapid COVID-19 antigen test, demonstrating their commitment to public health. Avacta received the CE Mark certification for its clinically validated SARS-CoV-2 rapid antigen test, facilitating global distribution. Such accomplishments highlight Avacta Group PLC's dedication to innovation, collaborations, and advancing healthcare solutions.

Avacta Group PLC is a leading biotechnology company, specializing in the development and commercialization of cutting-edge technologies. With a rich history and strong background, Avacta has been at the forefront of innovative solutions since its inception. Established in 2004 and headquartered in the United Kingdom, Avacta has built a solid reputation for its expertise in Affimer® technology, an alternative to antibodies. Avacta's extensive portfolio includes products and services for various sectors, including diagnostics, therapeutics, and research. With a commitment to revolutionizing the healthcare industry, Avacta Group PLC continues to drive advancements in precision medicine and deliver transformative solutions for global health challenges.

The main competitors of Avacta Group PLC in the market are companies like Abcam, Bio-Rad Laboratories, and Thermo Fisher Scientific.

Avacta Group PLC is primarily active in the biotechnology and healthcare industries.

The business model of Avacta Group PLC revolves around the development and commercialization of innovative life science tools and technologies. Avacta Group specializes in the development of Affimer® platform, a versatile technology with multiple applications in diagnostics, therapeutics, and research. The company aims to leverage its proprietary technology to provide solutions for various sectors including biotechnology, healthcare, and pharmaceuticals. Avacta Group focuses on collaborations and partnerships to accelerate commercialization and maximize the potential of its Affimer® platform. Through its dedication to innovation and strategic partnerships, Avacta Group aims to drive growth and create value for shareholders and stakeholders.

Poměr Avacta Group P/E je -6,02.

Koeficient Avacta Group tržních hodnot je 8,81.

AlleAktien kvalitní skóre pro Avacta Group je 6/10.

očekávané Avacta Group obrat je 24,76 mil. GBP.

očekávané Avacta Group zisk je -36,22 mil. GBP.

The Avacta Group PLC is a biotechnology and diagnostics company specialized in the development and commercialization of technologies and applications in the life sciences and healthcare sectors. The company offers innovative products and services for disease detection and treatment, as well as pharmaceutical research. It operates in two business areas: "Life Sciences" and "Animal Health." The "Life Sciences" business focuses on providing tools and services for drug discovery and therapy development, particularly in the field of recombinant affinity reagents. The "Animal Health" business concentrates on developing diagnostic tests for various animals, including dogs, cats, horses, and cattle. Avacta's products include affinity reagents, reactive surfaces, assays, and devices for both research and clinical use. The company has also developed a proprietary immunoclonal format called Affimer, which is an alternative to antibodies for biomarker detection and quantification. Avacta offers custom services for Affimer applications. Established in 2004, Avacta Group is listed on the London Stock Exchange and headquartered in Wetherby, Yorkshire, with additional offices in Cambridge and San Diego. The company collaborates with customers and partners in the biotechnology, pharmaceutical, and diagnostics sectors to develop innovative products. It aims to expand its leadership position in biotechnology and diagnostics by continually enhancing its product and service pipeline.Most relevantly, Avacta Group provides a wide range of products and services in the life sciences and animal health sectors, employing advanced technologies for disease detection and treatment. It is committed to promoting biotechnological research and development and delivering innovative products for clinical application.

Avacta Group vyplácí dividendu ve výši 0 GBP rozdělenou do výplat během roku.

Dividenda pro Avacta Group momentálně nemůže být vypočítána nebo společnost žádnou dividendu nevyplácí.

ISIN společnosti Avacta Group je GB00BYYW9G87.

WKN společnosti Avacta Group je A2ADP0.

Ticker společnosti Avacta Group je AVCT.L.

Během posledních 12 měsíců vyplatila společnost Avacta Group dividendu ve výši . To odpovídá dividendovému výnosu přibližně . Pro nadcházejících 12 měsíců se očekává, že Avacta Group vyplatí dividendu ve výši 0 GBP.

Výnos z dividend společnosti Avacta Group aktuálně činí .

Avacta Group vyplácí čtvrtletní dividendu. Ta je distribuována v měsících .

Avacta Group vyplácela v posledních 0 letech každý rok dividendu.

Očekává se, že v následujících 12 měsících budou dividendy ve výši 0 GBP. To odpovídá dividendovému výnosu 0 %.

Avacta Group je přiřazen k sektoru 'Zdraví'.

Aby ses mohl podílet na poslední dividendě Avacta Group ve výši 0 GBP, zaznamenané 14. 7. 2024, měl jsi mít akcii ve svém portfoliu před ex-dnem 14. 7. 2024.

Poslední dividendy byly vyplaceny dne 14. 7. 2024.

V roce 2023 společností Avacta Group bylo vyplaceno 0 GBP ve formě dividend.

Dividendy společnosti Avacta Group jsou vypláceny v GBP.